Details

Autor(en) / Beteiligte

• Jensen, S. B.
• Pedersen, A. M. L.
• Vissink, A.
• Andersen, E.
• Brown, C. G.
• Davies, A. N.
• Dutilh, J.
• Fulton, J. S.
• Jankovic, L.
• Lopes, N. N. F.
• Mello, A. L. S.
• Muniz, L. V.
• Murdoch-Kinch, C. A.
• Nair, R. G.
• Napeñas, J. J.
• Nogueira-Rodrigues, A.
• Saunders, D.
• Stirling, B.
• von Bültzingslöwen, I.
• Weikel, D. S.
• Elting, L. S.
• Spijkervet, F. K. L.
• Brennan, M. T.

Titel

A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact

Ist Teil von

• Supportive care in cancer, 2010-08, Vol.18 (8), p.1061-1079

Ort / Verlag

Berlin/Heidelberg: Springer-Verlag

Erscheinungsjahr

2010

Link zum Volltext

Quelle

SpringerLink (Online service)

Beschreibungen/Notizen

• Purpose This systematic review aimed to assess the literature for management strategies and economic impact of salivary gland hypofunction and xerostomia induced by cancer therapies and to determine the quality of evidence-based management recommendations. Methods The electronic databases of MEDLINE/PubMed and EMBASE were searched for articles published in English since the 1989 NIH Development Consensus Conference on the Oral Complications of Cancer Therapies until 2008 inclusive. For each article, two independent reviewers extracted information regarding study design, study population, interventions, outcome measures, results, and conclusions. Results Seventy-two interventional studies met the inclusion criteria. In addition, 49 intensity-modulated radiation therapy (IMRT) studies were included as a management strategy aiming for less salivary gland damage. Management guideline recommendations were drawn up for IMRT, amifostine, muscarinic agonist stimulation, oral mucosal lubricants, acupuncture, and submandibular gland transfer. Conclusions There is evidence that salivary gland hypofunction and xerostomia induced by cancer therapies can be prevented or symptoms be minimized to some degree, depending on the type of cancer treatment. Management guideline recommendations are provided for IMRT, amifostine, muscarinic agonist stimulation, oral mucosal lubricants, acupuncture, and submandibular gland transfer. Fields of sparse literature identified included effects of gustatory and masticatory stimulation, specific oral mucosal lubricant formulas, submandibular gland transfer, acupuncture, hyperbaric oxygen treatment, management strategies in pediatric cancer populations, and the economic consequences of salivary gland hypofunction and xerostomia.